Delivery Order SPE2DB20D2104-SPE2DB22FU07H
- Not listed
- This federal contract award, valued at $2,299.32, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The award is for the delivery of 4558244987 – LIDOCAINE 5% PATCH 30S, a pharmaceutical product. The contract has a firm fixed price and ultimate completion date of August 29, 2022. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- This federal contract award is a delivery order valued at $1,202.00 issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The order is for 4559509218 - LIDOCAINE 5% PATCH 30S, a pharmaceutical product. The contract has an ultimate completion date of January 6, 2023 and was awarded on January 5, 2023. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- This federal contract award, valued at $9,693.84, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the delivery of LIDOCAINE 5% PATCH 30S, a medical product, with a completion date of May 16, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which is a for-profit organization registered in the System for Award Management (SAM.gov). The...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of LIDOCAINE 5% PATCH 30S. The contract has an award value of $1,500.80 and a completion date of March 27, 2025. It is a Firm Fixed Price Delivery Order contract, without any set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
- This federal contract award, valued at $3,192.41, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4567806976 LIDOCAINE 5% PATCH 30S, a medical product. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of April 7, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) valued at $999,999,999 with the DLA...
- This federal contract award, valued at $9,856.90, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LIDOCAINE 5% PATCH 30S, a medical product, and has an ultimate completion date of July 29, 2024. The contract is a Delivery Order, with a Firm Fixed Price pricing type, and was not set aside for any specific business category. AmerisourceBergen Drug Corp holds...
- This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,181.76 firm fixed-price contract is for the delivery of LIDOCAINE 5% PATCH 30S, a medical product, with a performance period through May 30, 2025. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC)...
- This federal contract award, valued at $3,889.37, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division. The contract is for the delivery of 4565427458 - LIDOCAINE 5% PATCH 30S, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of August 13, 2024. This award is not associated with a set-aside designation. Amerisourcebergen is a major supplier of pharmaceutical...
- This federal contract award, valued at $1,623.17, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4568207941 LIDOCAINE 5% PATCH 30S, a medical product, with a performance period extending through May 12, 2025. The contract is designated as a Firm Fixed Price Delivery Order, with no set-aside requirements. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
- This federal contract award, valued at $1,425.03, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of 4563982189 - LIDOCAINE 5% PATCH 30S, a pharmaceutical product. The contract is a firm-fixed-price delivery order with a performance period through March 18, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00 through...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB22FU07HDelivery Order
This federal contract award, valued at $1,822.80, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4558614406 - LIDOCAINE 5% PATCH 30S, a medical product. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of September 28, 2022. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. Amerisourcebergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs. These contracts demonstrate Amerisourcebergen's capacity to meet the diverse and critical pharmaceutical needs of multiple government agencies on a large scale.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 9/27/22 |